FDA Output
FDA Output, January 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in January 2026. Updated January 31.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Investors & Dealmaking
As Angelini Ventures Raises Its Global Profile, Neurotech Is on Its Radar
The Italian corporate venture firm doubled down on its commitment to CoMind this fall, indicating its global interest in connected health and in particular novel approaches to challenging problems in neurological conditions.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Regulatory & Reimbursement
Pathways' Pick of the Week: ARPA-H Seeks AI Cardiologist
Agentic AI plans solicited to fill a cardiologist gap. Excerpted from Pathways’ Picks January 21: AI Cardiologist, Record-Setting FDA Approvals, EU Inspections Effort.